298 patents
Page 12 of 15
Utility
Pyrazolopyridine Compounds and Uses Thereof
9 Sep 20
Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds.
Kai Liu, Jun Pan, Alexander Sokolsky, Oleg Vechorkin, Hai Fen Ye, Qinda Ye, Wenqing Yao
Filed: 9 Feb 20
Utility
Heterocyclic Compounds As Immunomodulators
9 Sep 20
Zhiyong Yu, Liangxing Wu, Wenqing Yao
Filed: 16 Apr 20
Utility
JAK1 Pathway Inhibitors for the Treatment of Chronic Lung Allograft Dysfunction
9 Sep 20
This disclosure relates to JAK1 pathway inhibitors and the use thereof in treating chronic lung allograft dysfunction such as, e.g., bronchiolitis obliterans syndrome.
Richard L. Schaub, Kevin O`Hayer
Filed: 4 Mar 20
Utility
Crystalline Solid Forms of a Bet Inhibitor
9 Sep 20
The present application relates to crystalline solid forms of an inhibitor of BET proteins such as BRD2, BRD3, BRD4, and BRD-t, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of diseases such as cancer.
Shili Chen, Zhongjiang Jia, Pingli Liu, Lei Qiao, Yongzhong Wu, Jiacheng Zhou, Qun Li
Filed: 23 Mar 20
Utility
Heterocyclic Compounds As Immunomodulators
2 Sep 20
Liangxing Wu, Kaijiong Xiao, Wenqing Yao
Filed: 4 Mar 20
Utility
Crystalline Forms of a FGFR Inhibitor and Processes for Preparing the Same
26 Aug 20
The present disclosure relates to solid forms of N-{[2′-(2,6-difluoro-3,5-dimethoxyphenyl)-3′-oxo-2′,3′-dihydro-1′H-spiro[cyclopropane-1,4′-[2,7]naphthyridin]-6′-yl]methyl}acrylamide, methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of the FGFR-associated or mediated diseases such as cancer.
Yongchun Pan, Chongsheng Eric Shi, Ming Tao, Wayne Han, Michael Xia, Dengjin Wang, Zhongjiang Jia, Jiacheng Zhou, Qun Li
Filed: 5 Feb 20
Utility
Pyrazolopyridines and Triazolopyridines As A2A / A2B Inhibitors
26 Aug 20
Taisheng Huang, Xiaozhao Wang
Filed: 27 Jan 20
Utility
Sustained Release Dosage Forms for a JAK1 Inhibitor
12 Aug 20
This invention relates to sustained release dosage forms comprising {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof, and doses and methods related thereto.
Krishnaswamy Yeleswaram, Bhavnish Parikh, Dilip P. Modi, Trupti Sheth
Filed: 16 Jan 20
Utility
Heterocyclic Compounds As Immunomodulators
12 Aug 20
Liangxing Wu, Jingwei Li, Wenqing Yao
Filed: 22 Apr 20
Utility
IMIDAZO[1,2-B][1,2,4]TRIAZINES As C-met Inhibitors
5 Aug 20
The present invention relates to imidazo[1,2-b][1,2,4]triazines that are inhibitors of c-Met and are useful in the treatment of c-Met associated diseases including cancer.
Jincong Zhuo, Chunhong He, Wenqing Yao
Filed: 3 Oct 19
Utility
Bicyclic Heteroarylaminoalkyl Phenyl Derivatives As PI3K Inhibitors
5 Aug 20
Yun-Long Li, Andrew P. Combs
Filed: 7 Oct 19
Utility
Salts of the Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-YL)-1H-Pyrazol-1-YL)-3- Cyclopentylpropanenitrile
24 Jun 20
The present invention provides salt forms of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile that are useful in the modulation of Janus kinase activity and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
Hui-Yin Li, James D. Rodgers
Filed: 1 Mar 20
Utility
JAK1 Pathway Inhibitors for the Treatment of Gastrointestinal Disease
24 Jun 20
This disclosure relates to JAK1 pathway inhibitors and the use thereof in treating gastrointestinal diseases or disorders such as ulcerative colitis.
Krishnaswamy Yeleswaram, Paul Smith, Gregory F. Hollis
Filed: 18 Dec 19
Utility
Imidazopyridazine and Imidazopyridine Compounds and Uses Thereof
24 Jun 20
Jun Pan, Jeremy Roach, Song Mei, Chunhong He, Liangxing Wu, Wenqing Yao
Filed: 18 Dec 19
Utility
Cyclopropylamines As LSD1 Inhibitors
10 Jun 20
The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
Liangxing Wu, Chunhong He, Ding-Quan Qian, Bo Shen, Wenqing Yao
Filed: 19 Nov 19
Utility
Pyrrolopyrimidine Derivatives As Tam Inhibitors
10 Jun 20
Yun-Long Li, David M. Burns, Hao Feng, Joseph Glenn, Chunhong He, Taisheng Huang, Song Mei, Jun Pan, Xiaozhao Wang, Yingda Ye
Filed: 14 Nov 19
Utility
Heterocyclic Compounds As Immunomodulators
10 Jun 20
Liang Lu, Ding-Quan Qian, Liangxing Wu, Wenqing Yao
Filed: 3 Feb 20
Utility
Pharmaceutical Compositions and Methods for Indoleamine, 2, 3-DIOXYGENASE Inhibition and Indications Therefor
10 Jun 20
The present invention is directed to pharmaceutical compositions of an inhibitor of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders.
Krishnaswamy Yeleswaram, Jack Guoen Shi
Filed: 8 Jan 20
Utility
Low Dose Combination Therapy for Treatment of Myeloproliferative Neoplasms
10 Jun 20
The present application relates to treatment of myeloproliferative neoplasms using the JAK1/JAK2 inhibitor, ruxolitinib, in combination with a low dose of a Pim inhibitor, N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide, wherein the combination is unexpectedly synergistic at a very low dose of the Pim inhibitor.
Holly Koblish, Gary Reuther
Filed: 5 Feb 20
Utility
Heterocyclic Compounds As Immunomodulators
3 Jun 20
Liangxing Wu, Fenglei Zhang, Song Mei, Wenqing Yao
Filed: 3 Feb 20